Quantcast

Posts related to ‘CEGE’

Biotech & BioHealth Business Daily (PFE, MRK, BAX, BDSI, SPPI, GNBT, AVII, CEGE, BBH, GILD, LLY, SNY, BMY, OSIP)

Posted: July 13, 2009 at 10:25 am

Here are some of today's top stories affecting key drug and biotech stocks, accompanied with links through to more detailed information and analysis at BioHealthInvestor.com: New short-interest data suggest traders ...
Read Full Story »
Burning Money Pic

Many Biotechs Barely On Life Support (BPAX, CEGE, EPIX, IDMI, LJPC, NRGN, NFLD, TPTX)

Posted: May 13, 2009 at 11:31 am

We have run a watch list of companies under their own strategic review, and the number of biotech (or grouped with biotech) stocks under this description is just staggering.   We ...
Read Full Story »
cammonopoly_wideweb__430x32501

Best Performing Sectors This Week: Cancer Stocks, Home Furnishing, Aircraft Leasing

Posted: April 16, 2009 at 12:07 pm

(more...) ...
Read Full Story »
Sad_clown

The 52-Week Low Club 9/8/2008 (FRE)(FNM)(BIOD)(AUTH)(CEGE)

Posted: September 8, 2008 at 2:55 pm

Freddie Mac (FRE) is one sale at $.65. A day-trader's dream, down from a 52-week high of $65.88.Fannie Mae (FNM) Almost a better deal. Sells off to $.65 from 52-week ...
Read Full Story »
Sad_clown

The 52-Week Low Club 8/27/2008 (F)(NEXM)(CEGE)(AMLN)

Posted: August 27, 2008 at 2:54 pm

Ford (F) Oil moves up. Drops to $4.25 from a 52-week high of $9.24.Nexmed (NEXM) Drug trial problems. Falls to $.23 from a 52-week high of $.1.87.Cell Genesys (CEGE) Drug ...
Read Full Story »
95129c

24/7 Wall St. Most Overpaid CEO Of The Day: Cell Genesys (CEGE) CEO Stephen A. Sherwin, M.D

Posted: August 27, 2008 at 8:41 am

Cell Genesys CEO Stephen A. Sherwin, M.D made $1.3 million last year, with $577,500 coming from base salary. He did so well, in the eyes of the board, that his ...
Read Full Story »

Biotech Business Daily (AMAG, CEGE, IMCL, XOMA, TRCA)

Posted: May 12, 2008 at 1:21 pm

AMAG Pharmaceuticals (NASDAQ: AMAG) has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI) beginning May 19, 2008. AMAG shares up $1.26 at $39.85. The 52-week range is $38.16 to ...
Read Full Story »

Cell Genesys Scores $30 Million Premium Financing (CEGE)

Posted: May 12, 2008 at 9:43 am

Cell Genesys, Inc. (NASDAQ: CEGE) plans to offer 7.1 million shares of common stock and warrants at an equivalent of $4.22 per share with a single institutional investor, for an ...
Read Full Story »

Cell Genesys Scores Takeda Deal (CEGE)

Posted: March 31, 2008 at 3:39 pm

Cell Genesys, Inc. (NASDAQ: CEGE) has announced a global alliance with Takeda Pharmaceutical Company Limited in Japan.  The companies will develop and commercialize Cell Genesys' GVAX immunotherapy for prostate cancer, ...
Read Full Story »

Major Biotech Movers (AGEN, CEGE, ENCY, IDMI, IMCL, ONXX, PFE, NTII, OXGN, PSDV, SIRT)

Posted: February 20, 2008 at 1:13 pm

Antigenics Inc.  (NASDAQ: AGEN) A study for Cancer vaccine, Oncophage, for the treatment of metastatic melanoma showed mixed results this morning. Shares are down almost 7% to $2.17. The 52 ...
Read Full Story »

The Day In Biotech Stocks (January 15, 2008) (DNA, DNDN, GENZ, TTHI, LCBM, CEGE, GPCB, CGEN)

Posted: January 15, 2008 at 7:07 pm

Today was a brutal day for risk stocks, and biotechs are often thought of as risky to stocks as Russian Roulette is to your head.  But Biotechs are also a ...
Read Full Story »

Short Selling Volatile Biotechs (June 2007) (DNDN, NFLD, NSTK, ADLR, ALTH, COLY, CEGE, NUVO)

Posted: June 27, 2007 at 12:36 pm

Stock Tickers: DNDN, NFLD, NSTK, ADLR, ALTH, COLY, CEGE, NUVOMany of the recent biotech implosions are always interesting to see if short sellers are getting out of the way or ...
Read Full Story »

Vertex Options Active Ahead of Data Presentation

Posted: April 13, 2007 at 10:53 am

Vertex (VRTX-NASDAQ) is seeing quite a bit of trading today ahead of a data presentation tomorrow.  This one may have been very active all on its own, but since Dendreon ...
Read Full Story »

Cell Genesys Slips New Holders a Mickey

Posted: April 11, 2007 at 7:53 am

Cell Genesys, Inc. (CEGE-NASDAQ) has done what many small biotechs do that are in need of cash: sell shares in a private placement "PIPE" after a sharp stock run-up.  It ...
Read Full Story »